Abingdon, Stason in Services Pact

Abingdon Life Sciences has entered into an agreement with Stason Pharmaceuticals to provide clinical and regulatory support for Stason’s drug development programs. As part of the agreement, Abingdon will provide clinical and regulatory services for Stason’s pipeline of potential drug candidates and devices in the areas of cancer and inflammation.  

“We are extremely happy to have formalized our relationship with Stason, and believe that this represents a synergistic opportunity for both our companies to leverage our respective core competencies in drug development and manufacturing,” said Richard Lebovitz, Abingdon’s chief executive officer.

Harry Fan, chief executive officer of Stason, added, “Stason is pleased to have agreed to this strategic partnership with Abingdon. It is a mutually beneficial relationship bringing expertise in many areas to our clients, both here in the US and in our overseas markets.”